The approval comes as reports of shortages in monoclonal antibody treatment arise and cases spike
People at greater risk of becoming seriously ill from Covid-19 will likely have more treatment options in January.
That’s the forecast in the wake of the US Food and Drug Administration’s approval this week of the first two antiviral pills used to treat Covid-19 and reports of shortages of a monoclonal antibody treatment used against the Omicron variant.
